Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹54.70|
|52 Week High||₹24.50|
|52 Week Low||₹75.00|
|1 Month Change||-7.68%|
|3 Month Change||-18.11%|
|1 Year Change||98.19%|
|3 Year Change||132.77%|
|5 Year Change||123.72%|
|Change since IPO||-50.72%|
Recent News & Updates
|500288||IN Pharmaceuticals||IN Market|
Return vs Industry: 500288 exceeded the Indian Pharmaceuticals industry which returned 24.7% over the past year.
Return vs Market: 500288 exceeded the Indian Market which returned 69.5% over the past year.
Stable Share Price: 500288 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 500288's weekly volatility (6%) has been stable over the past year.
About the Company
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac.
Morepen Laboratories Fundamentals Summary
|500288 fundamental statistics|
Is 500288 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500288 income statement (TTM)|
|Cost of Revenue||₹8.91b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||2.41|
|Net Profit Margin||8.14%|
How did 500288 perform over the long term?See historical performance and comparison
Is Morepen Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500288 (₹54.7) is trading above our estimate of fair value (₹12.41)
Significantly Below Fair Value: 500288 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500288 is good value based on its PE Ratio (22.7x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: 500288 is poor value based on its PE Ratio (22.7x) compared to the Indian market (22.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500288's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500288 is overvalued based on its PB Ratio (5.8x) compared to the IN Pharmaceuticals industry average (3.2x).
How is Morepen Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Morepen Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Morepen Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500288 has high quality earnings.
Growing Profit Margin: 500288's current net profit margins (8.1%) are higher than last year (4.9%).
Past Earnings Growth Analysis
Earnings Trend: 500288's earnings have grown significantly by 40.5% per year over the past 5 years.
Accelerating Growth: 500288's earnings growth over the past year (138.9%) exceeds its 5-year average (40.5% per year).
Earnings vs Industry: 500288 earnings growth over the past year (138.9%) exceeded the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 500288's Return on Equity (25.5%) is considered high.
How is Morepen Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 500288's short term assets (₹5.3B) exceed its short term liabilities (₹4.0B).
Long Term Liabilities: 500288's short term assets (₹5.3B) exceed its long term liabilities (₹300.6M).
Debt to Equity History and Analysis
Debt Level: 500288's debt to equity ratio (43.7%) is considered high.
Reducing Debt: 500288's debt to equity ratio has increased from 34% to 43.7% over the past 5 years.
Debt Coverage: 500288's debt is well covered by operating cash flow (27.4%).
Interest Coverage: 500288's interest payments on its debt are well covered by EBIT (69.6x coverage).
What is Morepen Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 500288's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 500288's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 500288's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 500288's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 500288's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sushil Suri (57 yo)
Mr. Sushil Suri, B.Sc., FCA has been Managing Director of Morepen Laboratories Limited since October 2000. He has been Chairman of Morepen Laboratories Limited since October 2000 and has been its Director...
CEO Compensation Analysis
Compensation vs Market: Sushil's total compensation ($USD716.55K) is above average for companies of similar size in the Indian market ($USD287.82K).
Compensation vs Earnings: Sushil's compensation has increased by more than 20% in the past year.
Experienced Management: 500288's management team is seasoned and experienced (7 years average tenure).
Experienced Board: 500288's board of directors are seasoned and experienced ( 16.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Morepen Laboratories Limited's employee growth, exchange listings and data sources
- Name: Morepen Laboratories Limited
- Ticker: 500288
- Exchange: BSE
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹24.605b
- Shares outstanding: 449.83m
- Website: https://www.morepen.com
Number of Employees
- Morepen Laboratories Limited
- 409, Antriksh Bhawan
- 4th Floor
- New Delhi
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 12:02|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.